Madrigal Pharmaceuticals, Inc. (MDGL)
Automate Your Wheel Strategy on MDGL
With Tiblio's Option Bot, you can configure your own wheel strategy including MDGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDGL
- Rev/Share 42.7204
- Book/Share 26.8646
- PB 16.2962
- Debt/Equity 0.588
- CurrentRatio 4.0149
- ROIC -0.3158
- MktCap 9942832562.0
- FreeCF/Share -8.4701
- PFCF -52.3252
- PE -34.0689
- Debt/Assets 0.2813
- DivYield 0
- ROE -0.4376
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MDGL | Barclays | -- | Overweight | -- | $964 | Jan. 28, 2026 |
| Downgrade | MDGL | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 6, 2026 |
| Upgrade | MDGL | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Nov. 5, 2025 |
| Upgrade | MDGL | BofA Securities | Underperform | Neutral | -- | $445 | Nov. 3, 2025 |
| Initiation | MDGL | Truist | -- | Buy | -- | $580 | Oct. 15, 2025 |
| Resumed | MDGL | H.C. Wainwright | -- | Buy | -- | $500 | Sept. 4, 2025 |
| Upgrade | MDGL | B. Riley Securities | Neutral | Buy | $236 | $422 | Feb. 28, 2025 |
| Reiterated | MDGL | H.C. Wainwright | -- | Buy | $400 | $405 | Feb. 27, 2025 |
News
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Negative
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Read More
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
Read More
What to Expect From These Drug/Biotech Players This Earnings Season?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Neutral
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Read More
MDGL Strengthens MASH Franchise With New Genetic Approaches
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.
Read More
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
MKKGY or MDGL: Which Is the Better Value Stock Right Now?
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either Merck KGaA (MKKGY) or Madrigal (MDGL). But which of these two stocks presents investors with the better value opportunity right now?
Read More
STVN or MDGL: Which Is the Better Value Stock Right Now?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either Stevanato Group (STVN) or Madrigal (MDGL). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
MDGL Secures Exclusive Global Right for MASH Treatment From PFE
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.
Read More
UTHR or MDGL: Which Is the Better Value Stock Right Now?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Madrigal (MDGL). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. We've made it to our last day of our London Healthcare Conference.
Read More
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., …
Read More
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago.
Read More
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
MDGL's Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 patients by Q2 2025. The EU also granted Rezdiffra a conditional authorization. It will soon launch in Germany, and it has a sizeable initial European target of diagnosed F2–F3 patients.
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Presentation Unknown Analyst Good morning, everyone. Very excited to be kicking off the Morgan Stanley Healthcare Conference with the Madrigal team this morning.
Read More
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Read More
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
Published: August 15, 2025 by: Seeking Alpha
Sentiment: Positive
Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmaceuticals still reported a net loss of $42.3M, though profitability may be near. Approval of Rezdiffra in the EU could come in August 2025, with a launch by MDGL in Germany in H2 '25 possible.
Read More
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
Read More
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.
Read More
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.
Read More
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Read More
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Read More
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by.
Read More
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Read More
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago.
Read More
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Read More
About Madrigal Pharmaceuticals, Inc. (MDGL)
- IPO Date 2007-02-06
- Website https://www.madrigalpharma.com
- Industry Biotechnology
- CEO William J. Sibold
- Employees 528